Stoke Therapeutics (NASDAQ: STOK) revenue
Stoke Therapeutics reported revenue of $184.4m for fiscal 2025, 404.5% more than in fiscal 2024 ($36.6m). Since fiscal 2022 its revenue has grown by 1,386.7%, an average growth of 145.9% a year.
Stoke Therapeutics has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 4 fiscal years on record. The biggest drop was in fiscal 2023, −29.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $184.4m | +404.5% | −$20.6m | −11.2% |
| 2024 | $36.6m | +316.3% | −$101.4m | −277.3% |
| 2023 | $8.8m | −29.2% | −$114.8m | −1,307.2% |
| 2022 | $12.4m | — | −$104.4m | −841.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Stoke Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Stoke Therapeutics ranks 254th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Stoke Therapeutics, 404.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 252nd | Rhythm Pharmaceuticals | $189.8m | 45.8% |
| 253rd | Maravai LifeSciences | $185.7m | −28.3% |
| 254th | Stoke Therapeutics | $184.4m | 404.5% |
| 255th | Phathom Pharmaceuticals | $175.1m | 216.9% |
| 256th | Syndax Pharmaceuticals | $172.4m | 627.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Stoke Therapeutics
- How much revenue did Stoke Therapeutics make in fiscal 2025?
- Stoke Therapeutics reported revenue of $184.4m for fiscal 2025, compared with $36.6m in fiscal 2024.
- How much has the revenue of Stoke Therapeutics grown?
- Between fiscal 2022 and fiscal 2025 it went from $12.4m to $184.4m: 1,386.7% more, an average growth of 145.9% a year.
- What was the best year for revenue at Stoke Therapeutics?
- Of its last 4 fiscal years, fiscal 2025, with $184.4m.
- Where does Stoke Therapeutics rank in its sector by revenue?
- It ranks 254th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Stoke Therapeutics come from?
- From the annual report (Form 10-K) that Stoke Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Stoke Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Stoke Therapeutics: the Stoke Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.